分化型甲状腺癌的治疗

Treatment of Differentiated Thyroid Carcinomas.

作者信息

Lechner Melissa G, Praw Stephanie Smooke, Angell Trevor E

机构信息

Division of Endocrinology, Diabetes, and Metabolism, David Geffen School of Medicine, University of California Los Angeles, 10833 Le Conte Avenue, CHS 57-145, Los Angeles, CA 90095, USA.

Division of Endocrinology, Diabetes, and Metabolism, David Geffen School of Medicine, University of California, Los Angeles, 10833 Le Conte Avenue, CHS 57-145, Los Angeles, CA 90095, USA.

出版信息

Surg Pathol Clin. 2019 Dec;12(4):931-942. doi: 10.1016/j.path.2019.08.003. Epub 2019 Sep 27.

DOI:10.1016/j.path.2019.08.003

PMID:31672299

Abstract

Differentiated thyroid cancer (DTC) is the most common thyroid cancer and is frequently encountered in clinical practice. The incidence of DTC has increased significantly over the past three decades. Surgical resection, radioactive iodine (RAI), and levothyroxine suppression therapy remain the primary modalities for DTC treatment. Active surveillance for low-risk thyroid cancer may be an alternative to immediate surgery for appropriately selected patients. Patient characteristics influence treatment selection and intensity. In the subset of patients with progressive distant metastatic disease, not amenable to treatment with surgery or RAI, novel agents, including targeted therapies and immunotherapy, should be considered.

摘要

分化型甲状腺癌（DTC）是最常见的甲状腺癌，在临床实践中经常遇到。在过去三十年中，DTC的发病率显著增加。手术切除、放射性碘（RAI）和左甲状腺素抑制治疗仍然是DTC治疗的主要方式。对于低风险甲状腺癌，积极监测可能是为适当选择的患者提供的一种替代立即手术的方法。患者特征会影响治疗选择和强度。在患有进行性远处转移性疾病、不适合手术或RAI治疗的患者亚组中，应考虑包括靶向治疗和免疫治疗在内的新型药物。